Many BioTelemetry, Inc.(BEAT) Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock. BioTelemetry was Initiated by Dougherty & Company on Dec 2, 2016 to Buy, Price Target of the shares are set at $26.
Company has reported several Insider transactions to the SEC, on Sep 20, 2016, Fred Broadway (SVP – Sales Marketing) sold 1,151 shares at 18.50 per share price.On Sep 20, 2016, George Hrenko (SVP – Human Resources) sold 1,061 shares at 18.50 per share price.On Sep 13, 2016, Peter Ferola (General Counsel) sold 4,352 shares at 18.23 per share price.
BioTelemetry Last issued its quarterly earnings results on Nov 2, 2016. The company reported $0.21 EPS for the quarter, beating the analyst consensus estimate by $ 0.04. Analyst had a consensus of $0.17. The company had revenue of $53.10 million for the quarter, compared to analysts expectations of $52.92 million. The companys revenue was up 22.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.13 EPS.
BioTelemetry, Inc. (NASDAQ:BEAT) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 1.2 by 5 Brokerage Firm. 4 Wall Street Firms have rated the stock as a strong buys. 1 stock experts have also suggested a buy rating.
BioTelemetry, Inc. (NASDAQ:BEAT): 3 analysts have set the short term price target of BioTelemetry, Inc. (NASDAQ:BEAT) at $25. The standard deviation of short term price target has been estimated at $1, implying that the actual price may fluctuate by this value. The higher and the lower price estimates are $ 26 and $24 respectively.
BioTelemetry, Inc. (NASDAQ:BEAT) rose 3.35% or 0.8 points on Tuesday and made its way into the gainers of the day. After trading began at $23.95 the stock was seen hitting $25.5 as a peak level and $23.85 as the lowest level. The stock ended up at $24.65. The daily volume was measured at 620,249 shares. The 52-week high of the share price is $25.5 and the 52-week low is $9.57. The company has a market cap of $696 million.
BioTelemetry, Inc. provides ambulatory outpatient management solutions for monitoring clinical information regarding an individuals health. It is focused on the diagnosis and monitoring of cardiac arrhythmias, or heart rhythm disorders. BioTelemetry, Inc., formerly known as CardioNet, Inc., is headquartered in Conshohocken, Pennsylvania.